Literature DB >> 3474093

Enoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.

S Toon, K J Hopkins, F M Garstang, L Aarons, A Sedman, M Rowland.   

Abstract

The interaction between the new quinoline-azaquinoline antibiotic enoxacin and the oral anticoagulant warfarin was investigated in six healthy male volunteers. Enoxacin was found not to affect the hypoprothrombinemic response produced by warfarin but did produce a decrease in the clearance of the less pharmacologically potent enantiomer of warfarin, (R)-warfarin. The decreased clearance of (R)-warfarin produced by concomitant enoxacin administration was found to be a consequence of inhibition by enoxacin of the (R)-6-hydroxywarfarin metabolic pathway.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3474093     DOI: 10.1038/clpt.1987.104

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  29 in total

1.  The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin.

Authors:  Richard A Faaij; Jacobus Burggraaf; Rik C Schoemaker; Rik de Greef; Adam F Cohen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.

Authors:  R A Faaij; J Burggraaf; R C Schoemaker; R G M Van Amsterdam; A F Cohen
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 3.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 4.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

Review 5.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

6.  Pharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.

Authors:  W M Awni; Z Hussein; G R Granneman; K J Patterson; L M Dubé; J H Cavanaugh
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 7.  Enoxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J M Henwood; J P Monk
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 8.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

9.  Further insight into the stereoselective interaction between warfarin and cimetidine in man.

Authors:  I Niopas; S Toon; M Rowland
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

10.  Human liver microsomal metabolism of the enantiomers of warfarin and acenocoumarol: P450 isozyme diversity determines the differences in their pharmacokinetics.

Authors:  J J Hermans; H H Thijssen
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.